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Purpose: To evaluate the effect of tamsulosin, solifenacin, and combination therapy of 
two agents in improving the lower urinary tract symptoms of patients with indwelling 
double-J ureteral stents.
Materials and Methods: A total of 168 patients underwent placement of a double-J ure-
teral stent after retrograde ureteroscopy for urinary stone disease. All patients received 
polyurethane double-J ureteral stents (6 Fr, 24 or 26 cm), which were removed a mean 
of 14 days postoperatively. A total of 48 patients were given no medication (Group 1), 
43 patients were given tamsulosin 0.2 mg once daily (Group 2), 45 patients were given 
solifenacin 5 mg once daily (Group 3), and 32 patients were given a combination of two 
agents postoperatively (Group 4). International Prostate Symptom Score/quality of life 
(IPSS/QoL) and visual analogue pain scale (VAPS) questionnaires were completed by 
each patient at 1 day postoperatively and on the day of stent removal.
Results: In the total group of patients, the mean age was 50.24±12.90 years. There was 
a significant difference in the IPSS total score between group 1 and groups 3 and 4. 
Group 4 also differed significantly from group 1 in the irritative subscore. The ob-
structive subscore differed between groups 2 and 4 and group 1. There was a statistically 
significant difference between group 1 and group 4 in the QoL score. There were no sig-
nificant differences in the VAPS.
Conclusions: Combination therapy with tamsulosin and solifenacin improved both irri-
tative and obstructive symptoms more than in the other groups. Combination therapy 
should be strongly considered for patients who complain of stent-related symptoms.
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INTRODUCTION
Ureteral stents, which were introduced by Zimskind et al 
in 1967, are widely used for urinary tract disease [1]. The 
double-J stent, which is the most common form of ureteral 
stent, is used in obstructive pyelonephritis, intolerable 
acute renal colic, ureteral edema, ureter perforation fol-
lowing endoscopic procedures, and diseases such as stein-
strasse [2,3].
　Despite the usefulness of stents, however, patients expe-
rience various stent-related symptoms, such as pain, fre-
quency, and urgency, which cause a significant decrease in 
patient health-related quality of life (HRQoL) [4]. The etiol-
ogy of these symptoms is unknown. Thomas reported that 
an important factor of stent-related symptoms is the pres-
sure transmitted to the renal pelvis during urination and 
trigonal irritation by the intravesicular part of the stent [5]. 
For this reason, several attempts to minimize stent-related 
symptoms have recently been reported. Pharmacologic 
management is one such trial, especially the prescription 
of selective alpha-1-blockers and antimuscarinic agents. 
We believe that pharmacologic management is simpler and 
less invasive than other ways. The purpose of this article 
was therefore to analyze and assess the effectiveness of a 
selective alpha-1-blocker (tamsulosin) and antimuscarinic 
(solifenacin) in improving the lower urinary tract symp-Korean J Urol 2011;52:485-488
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TABLE 1. The characteristics of 168 patients
Group 1 Group 2 Group 3 Group 4 p-value
a
Patient (n)         48         43         45         32
Age
b (yr) 50.08±11.47 49.91±15.23 49.87±13.29 50.72±11.46 0.986
Gender 0.564
    Male         31         24         31         22
    Female         17         19         14         10
Stone location ＜0.001
    Upper ureter           7         12         14         14
    Mid ureter           5           0           3         10
    Lower ureter         36         31         28           8
a: chi-square test, 
b: Mean±SD
toms of patients with indwelling double-J ureteral stents.
MATERIALS AND METHODS
1. Materials
Between January 2010 and December 2010, 168 patients 
(108 men and 60 women) underwent double-J stenting ret-
rogradely after retrograde ureteroscopy for urinary stones 
by a single surgeon. Patient data were obtained retro-
spectively through chart review. Patients who were pre-
viously diagnosed with benign prostatic hyperplasia or 
overactive bladder and who were prescribed a selective al-
pha-1-blocker or antimuscarinic agent were excluded from 
this study. In addition, patients who were using analgesics 
before surgery were also excluded. The ureteral stent was 
composed of polyurethane material and its diameter was 
6 Fr; the lengths were 24 cm and 26 cm. The length of ureter-
al stent was dependent on the patient's height.
2. Methods
Surgery was performed under general anesthesia and the 
position of the stent was confirmed by plain X-ray. The 
stents were removed 14 days after surgery. The patients 
were divided into four groups. Group 1 (n=48) was the con-
trol group and did not take any drugs. Group 2 (n=43) re-
ceived tamsulosin 0.2 mg once a day every day. Group 3 
(n=45) received solifenacin 5 mg once a day every day. 
Group 4 (n=32) received tamsulosin 0.2 mg and solifenacin 
5 mg daily. The day before surgery, on postoperative day 
1, and on the day of stent removal, each patient completed 
written International Prostate Symptom Score/quality of 
life (IPSS/QoL) and visual analogue pain scale (VAPS) 
questionnaires. The IPSS was divided into the total score, 
obstructive symptom score, and irritative symptom score, 
and each was compared. Each group's preoperative day, 
postoperative day, and stent removal day scores were 
compared. Chi-square test, one-way ANOVA, and one-way 
repeated-measures ANOVA were used for comparisons be-
tween each of four groups. Values of p＜0.05 were consid-
ered statistically significant. Statistical analyses were per-
formed with SPSS ver. 18.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
The mean age of the patients was 50.24±12.90 years, and 
there were no significant differences between the groups. 
A total of 103 patients has lower ureter stones, whereas 18 
patients had mid ureter stones. The stone distribution was 
significantly different in each group (p＜0.001) (Table 1). 
There were statistically significant differences in the IPSS 
total score and the obstructive subscore by one-way re-
peated-measures ANOVA (p=0.013, 0.006). There were 
significant differences between group 1 and group 4 (p= 
0.015), and between group 2 and group 4 (p=0.031), in the 
IPSS total score. For the obstructive subscore, group 4 dif-
fered significantly from group 1 (p=0.003). There were no 
statistically significant differences in the irritative sub-
score, QoL, or VAPS (p=0.075, 0.068, and 0.088, re-
spectively). However, the p-value of interaction was stat-
istically significant for the IPSS total score, irritative sub-
score, obstructive subscore, and QoL (p＜0.001, ＜0.001, 
0.015, and 0.012, respectively).
　We therefore compared each group by one-way ANOVA 
at each time point. On the day of stent removal, all scores 
were significantly different in each group except the VAPS 
(p＜0.001, ＜0.001, ＜0.001, ＜0.001). In particular, all 
scores were significantly lower in group 4 except for VAPS. 
In group 2, only the obstructive score was significantly 
lower. The total and irritative subscore were significantly 
lower in group 3. Preoperatively and 1 day postoperatively, 
there were no significant differences in any group. The 
VAPS did not appear to significantly change in any groups 
(Table 2). According to the multiple comparison test on the 
day of stent removal, there was a significant decrease only 
in group 4. This suggests that that stent-related symptoms 
improved more in group 4 than in group 1. Symptoms did 
not significantly improve in the other groups.
　The side effects of tamsulosin and solifenacin were 
minimal. No patients discontinued the medication because 
of side effects.
DISCUSSION
Ureteral stents can be used variously in the management Korean J Urol 2011;52:485-488
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TABLE 2. Comparisons of IPSS/QoL and VAPS in group 1, 2, 3 and 4
Group 1 Group 2 Group 3 Group 4 p-value
a p-value
b
IPSS total score Preoperative   8.94±4.13   8.60±4.12   9.04±3.94   8.72±4.16 0.958
On one day postoperatively 11.65±4.38 12.53±4.79 11.16±5.13 11.47±3.98 0.013 (＜0.001)
c  0.552
On the day of stent removal 13.77±4.50 12.77±5.24 11.04±5.29   7.16±3.37 ＜0.001
T
d            1
        1, 2
           2
            3
IPSS irritative Preoperative   4.15±2.59   4.30±2.84   4.49±3.09   4.84±2.71 0.735
  subscore On one day postoperatively   6.44±3.46   7.79±3.69   6.27±4.00   7.09±3.52 0.075 (＜0.001)
c  0.201
On the day of stent removal   7.48±3.50   8.05±3.88   5.73±4.00   4.22±2.70 ＜0.001
T
d         1, 2
           1
         2, 3
            3
IPSS obstructive Preoperative   4.79±3.16   4.30±2.95   4.56±2.78   3.88±2.88 0.572
  subscore On one day postoperatively   5.21±2.57   4.74±2.91   4.89±2.73   4.38±2.54 0.006 (0.015)
c  0.592
On the day of stent removal   6.29±2.63   4.72±3.24   5.31±2.91   2.94±2.06     ＜0.001
T
d            1
           2
         1, 2
            3
QoL Preoperative   2.52±1.79   2.19±1.80   2.42±1.62   1.88±1.77 0.385
On one day postoperatively   2.21±1.76   2.44±1.71   2.51±1.74   2.34±1.56 0.068 (0.012)
c  0.844
On the day of stent removal   2.83±1.72   3.07±1.67   2.87±1.77   1.47±1.44 ＜0.001
T
d            1
           1
           1
            2
VAPS Preoperative   6.42±1.71   6.60±1.59   6.18±1.70   6.28±1.65
On one day postoperatively   2.56±1.47   2.88±1.50   2.69±1.46   2.44±1.37 0.088 (0.634)
c 
On the day of stent removal   2.90±1.65   3.67±1.94   2.87±1.87   2.69±1.31
IPSS/QoL: International Prostate Symptom Score and Quality of Life, VAPS: Visual analogue pain scale, 
a: one-way repeated measures
ANOVA, 
b: one-way ANOVA, 
c: p-value of interaction, 
d: the same letters indicate non-significant difference between groups based on
Tukey’s multiple comparison test
of urinary tract diseases. For example, for the prevention 
of ureteral obstruction and recovery of damaged ureter tis-
sue, narrowing the expansion of the ureter and the stone 
will help with emissions [2]. Ureteroscopy, especially after 
ureteroscopic lithotripsy, routinely make use of ureteral 
stents [6]. The use of ureteral stents aids in the improve-
ment of urinary tract disease, whereas patients with in-
dwelling stents have been known to complain of a variety 
of stent-related symptoms. In fact, flank pain, lower ab-
dominal pain or loin pain, frequency, urgency, infection, 
and hematuria are known stent-related symptoms [7]. 
Joshi et al reported that, because of these stent-related 
symptoms, 80% of patients have a reduced HRQoL and 
need continued understanding and interest about their 
symptoms [8]. To solve these problems, studies have been 
run in several ways. First, stent material changes have 
been tried to reduce the symptoms. For example, double-J 
stents with a tapered distal end made with a hydrophilic 
material were introduced [9]. In addition, studies about the 
relationship between stent length and morbidity have been 
reported. If a ureteral stent is needed after endoscopic sur-
gery, ureteral length should be measured so that an appro-
priate stent can be used in patients, which can reduce distal 
migration and stent-related symptoms [10]. Periureteral 
injection of botulinum toxin type A after stent insertion has 
been shown to decrease pain and narcotic requirement 
[11].
　We believe that new stent development is difficult. In ad-
dition, the cost and technical difficulties of botulinum toxin 
treatment are considered to be problems. We therefore 
sought safe and convenient ways to improve stent-related 
symptoms and we researched pharmacologic management 
as one of those ways. Stent-related symptoms are similar 
to the benign prostatic hyperplasia symptoms caused by 
urethral and bladder resistance and bladder instability 
[12]. For this reason, some studies have reported that se-
lective alpha-1-blockers improve stent-related symptoms. 
Beddingfield et al reported that patients taking alfuzosin 
10 mg daily had improved frequency and flank pain [13]. 
Furthermore, improvement of sleep disorders and daily life 
were also reported. Deliveliotis et al reported that alfuzo-
sin improved stent-related symptoms and pain as well as 
sexual function and general health [14]. Wang et al sug-
gested that the selective alpha-1-blocker tamsulosin im-
proved urinary symptoms, flank pain, and pain during 
voiding [15]. In addition, Damiano et al reported that the 
administration of tamsulosin improved urinary symp-
toms, VAPS, and QoL [12]. In our study, the IPSS total 
score, irritative subscore, QoL, and VAPS did not show 
statistically significant differences. However, the differ-
ence in the obstructive subscore was statistically signi-
ficant. 
　Stent-related symptoms are similar to overactive blad-
der symptoms (urinary frequency, urgency, and urge in-
continence) caused by involuntary bladder contraction 
mediated by muscarinic receptors [16]. Antimuscarinic 
agents have been used to improve overactive bladder 
symptoms. Norris et al reported that there were no sig-
nificant differences between an oxybutynin-treated group 
and a placebo group [17]. But those authors argued that fur-
ther ongoing research is needed. Agarwal et al reported 
that bladder discomfort was improved in an oxybutinin or Korean J Urol 2011;52:485-488
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tolterodine administration group compared with a placebo 
group before surgery [18]. In our study, the solifenacin 5 
mg daily group had statistically significant differences in 
the total score and irritative subscore. The other scores 
were not significantly different. 
　Lee et al compared combination treatment with tamsu-
losin and tolterodine with a placebo group [19]. Each group 
showed no significant differences in the IPSS or VAPS. 
They reported that correct stent location was more effective 
for the improvement of stent-related symptoms. In the 
present study, however, IPSS and QoL showed statistically 
significant differences in the tamsulosin and solifenacin 
combination treatment group. However, there was no sig-
nificant difference in the VAPS.
　The limitations of this study are as follows. Some pa-
tients did not complete the ureteral stent symptom ques-
tionnaire on the preoperative day. Therefore, we could not 
use this questionnaire. The small groups of each scale made 
it difficult to verify the statistical significance. Because this 
was a nonrandomized and retrospective study, we did not 
get useful and entirely credible information. Therefore, 
further large-scale, randomized, prospective study is need-
ed to get more accurate information.
CONCLUSIONS
　Combination therapy with tamsulosin and solifenacin 
improved obstructive and irritative symptoms and QoL 
more than in the control group. Therefore, combination 
therapy with tamsulosin and solifenacin should be strong-
ly considered for patients who complain of stent-related 
symptoms. In the future, large-scale, prospective, and 
randomized study will be needed.
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